---
title: Congenica announces Early Access Program for its novel Precision Oncology Solution
description: Congenica launches early access program for its new CE-IVD Precision Oncology Solution
image: https://blog.congenica.com/hubfs/Add%20a%20heading.png
---

- [Our Customers and Partners](http://www.congenica.com/our-customers)
- [Our Product Portfolio](http://www.congenica.com/congenica-products) 
    - **Inherited Diseases** 
          - [Rare Disease](http://www.congenica.com/congenica-rare-disease)
          - [Inherited Cancer](http://www.congenica.com/congenica-inherited-cancer)
          - [Prenatal Health](http://www.congenica.com/congenica-prenatal)
          - [Carrier Screening](http://www.congenica.com/congenica-carrier-screening)
          - [Neurodevelopmental Disorders](http://www.congenica.com/congenica-neuro)
    - **Somatic Oncology** 
          - [Solid Tumours](http://www.congenica.com/congenica-oncology)
    - **Pathogen** 
          - [Pathogen Surveillance](http://www.congenica.com/congenica-pathogen-surveillance)
- [Our Services](http://www.congenica.com/congenica-services) 
    - [Clinical Interpretation Services](http://www.congenica.com/congenica-clinical-interpretation-services)
    - [Professional Services](http://www.congenica.com/professional-services)
    - [Customer Support](http://www.congenica.com/customer-support)
    - [Pharma Services](http://www.congenica.com/pharma-services)
- Resources 
    - [Publications](http://www.congenica.com/publications)
    - [Supporting materials](http://www.congenica.com/resources)
    - [News](https://blog.congenica.com/)
    - [Events and webinars](http://www.congenica.com/events-webinars)
- [About us](http://www.congenica.com) 
    - [Leadership Team](http://www.congenica.com/leadership)
    - [Quality](http://www.congenica.com/quality)
    - [Investors](http://www.congenica.com/investors)
    - [People and Vacancies](http://www.congenica.com/people)
- [Contact us](http://www.congenica.com/contact)

Login

##### Please select your location and reference genome:

[America - GRCh37](https://us-37.congenica.com/) [America - GRCh38](https://us-38.congenica.com/) [Europe, Middle East, Africa - GRCh37](https://eu-37.congenica.com/) [Europe, Middle East, Africa - GRCh38](https://eu-38.congenica.com/)

[Overview](https://blog.congenica.com) [Congenica announces Early Access Program for its novel Precision Oncology Solution](https://blog.congenica.com/congenica-announces-ea-program-for-its-novel-precision-oncology-solution)

![Congenica announces Early Access Program for its novel Precision Oncology Solution](https://blog.congenica.com/hubfs/Add%20a%20heading.png)

 News

 precision oncology

# Congenica announces Early Access Program for its novel Precision Oncology Solution

 1/19/2023     |    0 min read

Cambridge, United Kingdom – 19 January 2023 - Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, is adding a novel CE-IVD Precision Oncology Solution to its Clinical Decision Support (CDS) Platform. 

Despite advances in biomarker-based drug approvals and availability, precision oncology medicine is still largely underutilised by clinicians worldwide. Congenica Oncology aims to democratise patient access by providing a fully automated and cost-effective end-to-end solution aimed at transforming the usability and scalability of genomic data for routine oncology clinical practice. 

Congenica’s novel platform enables unbiased, evidence-based interpretation of NGS data with focus on actionable insights for rapid treatment decisions powered by NCCN, ESMO, NICE and SMC best practice guidelines with authorised therapeutic assertions from the FDA, EMA, and MHRA.

   
The Early Access Program, which will be available for European customers from 19 January 2023, will initially support Illumina’s TSO500 panels. Additional commercial as well as custom panels will be added for launch later in the year.  

Alistair Johnson, Chief Professional Services Officer at Congenica, said: “The expansion of Congenica’s Clinical Decision Support (CDS) Platform into Oncology is a significant step for Congenica. Our universal platform is ideally placed to support genome-based analyses across a wide range of disease areas. Our novel Precision Oncology Solution offers a scalable, fully automated future-proof end-to-end solution that will drive precision medicine and deliver highest quality patient support.” 

For further information, please visit [Congenica Oncology Early Access Program](https://genomics.congenica.com/oncologyeaprprogram).

 

[![REGISTER FOR OUR EARLY ACCESS PROGRAM](https://no-cache.hubspot.com/cta/default/6863388/8fcd697b-016a-4df5-8c4f-1ea6cb72fe02.png)](https://cta-redirect.hubspot.com/cta/redirect/6863388/8fcd697b-016a-4df5-8c4f-1ea6cb72fe02)

---

<http://www.facebook.com/share.php?u=https://blog.congenica.com/congenica-announces-ea-program-for-its-novel-precision-oncology-solution&utm_medium=social&utm_source=facebook> <http://www.linkedin.com/shareArticle?mini=true&url=https://blog.congenica.com/congenica-announces-ea-program-for-its-novel-precision-oncology-solution&utm_medium=social&utm_source=linkedin> <https://twitter.com/intent/tweet?original_referer=https://blog.congenica.com/congenica-announces-ea-program-for-its-novel-precision-oncology-solution&utm_medium=social&utm_source=twitter&url=https://blog.congenica.com/congenica-announces-ea-program-for-its-novel-precision-oncology-solution&utm_medium=social&utm_source=twitter&source=tweetbutton&text=>

### Related articles

![SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine](https://blog.congenica.com/hs-fs/hubfs/New%20logos/Congenica%20%26%20SeqOne%20Logo%20Without%20Tagline%20RGB.png?width=320&height=192&name=Congenica%20%26%20SeqOne%20Logo%20Without%20Tagline%20RGB.png)

 9/2/2025

#### [SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine](https://blog.congenica.com/seqone-acquires-congenica-to-create-a-global-leader-in-ai-powered-genomic-medicine)

Strategic acquisition of UK genomics leader Congenica reinforces SeqOne market position and footprint - servicing over 160 labs in 30+ countries

![Congenica showcased in Genomics Spotlight 2024 Report](https://blog.congenica.com/hs-fs/hubfs/male%20doc%20with%20child%20and%20mum%20light%20small%20.jpg?width=320&height=192&name=male%20doc%20with%20child%20and%20mum%20light%20small%20.jpg)

 11/6/2024

#### [Congenica showcased in Genomics Spotlight 2024 Report](https://blog.congenica.com/congenica-showcased-in-recently-launched-genomics-spotlight-2024-report)

We are thrilled to announce that Congenica is one of the companies showcased in the recently launched Genomics Spotlight 2024 report produced by the UK Department for Business and Trade (DBT).

![Congenica Named Best Genomic Data Analysis Software Company 2024 by GHP](https://blog.congenica.com/hs-fs/hubfs/Onco%20.png?width=320&height=192&name=Onco%20.png)

 6/19/2024

#### [Congenica Named Best Genomic Data Analysis Software Company 2024 by GHP](https://blog.congenica.com/congenica-named-best-genomic-data-analysis-software-company-2024-by-ghp)

We are thrilled to announce that Congenica has been awarded the title of "Best Genomic Data Analysis Software Company 2024" by Global Health & Pharma Magazine. 

##### Congenica is available as a CE Marked IVD clinical decision support platform for clinical diagnostic use for inherited genetic disorders in the UK and EU, Iceland, Lichtenstein, Norway, Switzerland and Turkey. In all other countries, ensuring compliance with relevant local, national and international clinical laboratory regulations is the responsibility of the laboratory.

- [Privacy Policy](http://www.congenica.com/privacy-policy)
- [Cookie Policy](http://www.congenica.com/cookie-policy)

<https://twitter.com/congenica> <https://en-gb.facebook.com/congenica/> <https://www.linkedin.com/company/congenica/> 

Log in to Congenica

##### Please select your location and reference genome:

[America - GRCh37](https://us-37.congenica.com/) [America - GRCh38](https://us-38.congenica.com/) [Europe, Middle East, Africa - GRCh37](https://eu-37.congenica.com/) [Europe, Middle East, Africa - GRCh38](https://eu-38.congenica.com/)

![CE](https://blog.congenica.com/hs-fs/hubfs/CE.png?width=80&height=80&name=CE.png) ![ISO-27001](https://blog.congenica.com/hs-fs/hubfs/ISO-27001.jpg?width=80&height=80&name=ISO-27001.jpg) ![TR-Testmark_9000030872_EN_2024_CMYK](https://blog.congenica.com/hs-fs/hubfs/2023%20website%20images/TR-Testmark_9000030872_EN_2024_CMYK.png?width=80&height=80&name=TR-Testmark_9000030872_EN_2024_CMYK.png) ![HIPAA Compliant](https://blog.congenica.com/hs-fs/hubfs/HIPAA%20Compliant.png?width=80&height=80&name=HIPAA%20Compliant.png)

Copyright © 2026 Congenica Ltd. Company number: 8273616 Registered in England and Wales.